Although treatment with CuB leads to a significant reduction in chordoma cell viability, induction of apoptosis, and undetectable levels of brachyury, supporting the promising therapeutic potential of brachyury degradation, its non-selective toxicity should also result in adverse effects in normal cells [32]. Here, TBX1 is linked to chordoma.